Julian Baker’s Arbutus Biopharma ABUS Stock Holding History

Julian Baker’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-180,582	Closed	-$1.32M	–	98
2018 Q2	$1.32M	Hold	180,582	–	–	0.01%	101
2018 Q1	$903K	Hold	180,582	–	–	0.01%	103
2017 Q4	$912K	Hold	180,582	–	–	0.01%	109
2017 Q3	$1.12M	Hold	180,582	–	–	0.01%	105
2017 Q2	$650K	Hold	180,582	–	–	0.01%	108
2017 Q1	$587K	Hold	180,582	–	–	﹤0.01%	108
2016 Q4	$442K	Hold	180,582	–	–	﹤0.01%	121
2016 Q3	$621K	Hold	180,582	–	–	0.01%	124
2016 Q2	$628K	Hold	180,582	–	–	0.01%	123
2016 Q1	$746K	Hold	180,582	–	–	0.01%	121
2015 Q4	$804K	Hold	180,582	–	–	0.01%	122
2015 Q3	$1.1M	Hold	180,582	–	–	0.01%	117
2015 Q2	$2.14M	Hold	180,582	–	–	0.02%	100
2015 Q1	$3.15M	Sell	180,582 -303,574	-63%	-$6.22M	0.03%	91
2014 Q4	$7.33M	Hold	484,156	–	–	0.07%	57
2014 Q3	$10.2M	Hold	484,156	–	–	0.13%	44
2014 Q2	$6.32M	Hold	484,156	–	–	0.08%	61
2014 Q1	$10.4M	Sell	484,156 -15,844	-3%	-$285K	0.13%	47
2013 Q4	$3.98M	Buy	+500,000	New	+$4.16M	0.06%	69

Other funds holding ABUS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Julian Baker's ABUS Position: Q3 2018 in Review

Julian Baker sold out of Arbutus Biopharma (ABUS) in Q3 2018, closing a stake of 180,582 shares — an estimated $1.32M sold.

Julian Baker first reported a position in ABUS in Q4 2013 and held it in 19 quarters. The position peaked at $10.4M in Q1 2014. 88 funds tracked by Wall St. Rank hold ABUS as of Q3 2018.

Julian Baker reported no remaining Arbutus Biopharma position as of Q3 2018 after selling out during the quarter.
Julian Baker sold 180,582 Arbutus Biopharma shares in Q3 2018, an estimated $1.32M.
Julian Baker first reported a position in Arbutus Biopharma in Q4 2013 and held it in 19 quarters.
Julian Baker's Arbutus Biopharma position peaked at $10.4M in Q1 2014.
88 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.